SAR407899 is primarily investigated for its potential therapeutic applications in the field of oncology. It functions as a selective inhibitor of ROCK (Rho-associated coiled-coil containing protein kinase), which plays a significant role in regulating cell motility, proliferation, and survival. By targeting ROCK, this compound is studied for its ability to inhibit cancer cell invasion and metastasis, making it a promising candidate for treating aggressive cancers such as triple-negative breast cancer and other solid tumors. Additionally, its role in modulating the tumor microenvironment and enhancing the efficacy of other anticancer therapies is under exploration. Research is ongoing to evaluate its safety, pharmacokinetics, and potential as part of combination therapies in clinical settings.